Stabilisation of amorphous furosemide increases the oral drug bioavailability in rats

International Journal of Pharmaceutics

Volumn 490, Issue 1-2, 2015, Pages 334-340

  Nielsen, Line Hagner ^a   Rades, Thomas ^b   Müllertz, Anette ^b  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Amorphous; Furosemide; Glass solution; Oral bioavailability; Polyvinylpyrrolidone; Solid dispersion

Indexed keywords

AMORPHOUS SODIUM SALT OF FUROSEMIDE; FUROSEMIDE; POVIDONE; SODIUM; UNCLASSIFIED DRUG; GLASS; SOLUTION AND SOLUBILITY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; GLASS TRANSITION TEMPERATURE; HUMIDITY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MISCIBILITY; NONHUMAN; PH; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SPRAY DRYING; ADMINISTRATION AND DOSAGE; ANIMAL; BIOAVAILABILITY; CHEMISTRY; CRYSTALLIZATION; MALE; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES; SOLUBILITY; SOLUTION AND SOLUBILITY; SPRAGUE DAWLEY RAT; TRANSITION TEMPERATURE;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG COMPOUNDING; DRUG STABILITY; FUROSEMIDE; GLASS; HYDROGEN-ION CONCENTRATION; MALE; PHARMACEUTICAL SOLUTIONS; POVIDONE; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TRANSITION TEMPERATURE;

EID: 84934934783     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.05.063     Document Type: Article

References (36)

1. Akbuga, J., Gursoy, A., Kendi, E., 1988. The preparation and stability of fast release furosemide-pvp solid dispersion. Drug Dev. Ind. Pharm. 14, 1439-1464. doi: http://dx.doi.org/10.3109/03639048809151942.
2. Alves, L. D. S., De La Roca Soares, M. F., De Albuquerque, C. T., Da Silva, É. R., Vieira, A. C. C., Fontes, D. A. F., Figueirêdo, C. B. M., Soares Sobrinho, J. L., Rolim Neto, P. J., 2014. Solid dispersion of efavirenz in PVP K-30 by conventional solvent and kneading methods. Carbohydr. Polym. 104, 166-174. doi: http://dx.doi.org/10.1016/j. carbpol. 2014.01.027.
3. Avdeef, A., Tsinman, O., 2008. Miniaturized rotating disk intrinsic dissolution rate measurement: effects of buffer capacity in comparisons to traditional Wood's apparatus. Pharm. Res. 25, 2613-2627. doi: http://dx.doi.org/10.1007/s11095-008-9679-z.
4. Bates, S., Zografi, G., Engers, D., Morris, K., Crowley, K., Newman, A., 2006. Analysis of amorphous and nanocrystalline solids from their X-ray diffraction patterns. Pharm. Res. 23, 2333-2349. doi: http://dx.doi.org/10.1007/s11095-006-9086-2.
5. Bikiaris, D. N., 2011. Solid dispersions, Part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs. Expert Opin. Drug Deliv. 8, 1501-1519. doi: http://dx.doi.org/10.1517/17425247.2011.618181.
6. Chiou, P. W., Yu, B., Kuo, C.-Y., 2000. Comparison of digestive function among rabbits, guinea-pigs, rats and hamsters. I. performance, digestibility and rate of digesta passage asian-australasian. J. Anim. Sci. 13.
7. Chiou, W. L., Riegelman, S., 1971. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 60, 1281-1302. doi: http://dx.doi.org/10.1002/jps.2600600902.
8. Doherty, C., York, P., 1987. Mechanisms of dissolution of frusemide pvp solid dispersions. Int. J. Pharm. 34, 197-205. doi: http://dx.doi.org/10.1016/0378-5173 (87) 90, 180-3.
9. Doherty, C., York, P., 1989. Accelerated stability of an x-ray amorphous frusemidepolyvinylpyrrolidone solid dispersion. Drug Dev. Ind Pharm. 15, 1969-1987. doi: http://dx.doi.org/10.3109/03639048909052513.
10. Goud, R., Swarupa, G., Suresh, K., Pal, S., Manjunatha, S. G., Nambiar, S., Nangia, A., 2011. Novel furosemide cocrystals and selection of high solubility drug forms. J. Pharm. Sci. 101, 664-680. doi: http://dx.doi.org/10.1002/jps.
11. Granero, G. E., Longhi, M. R., Mora, M. J., Junginger, H. E., Midha, K. K., Shah, V. P., Stavchansky, S., Dressman, J. B., Barends, D. M., 2010. Biowaiver monographs for immediate release solid oral dosage forms: furosemide. J. Pharm. Sci. 99, 2544-2556. doi: http://dx.doi.org/10.1002/jps.22030.
12. Grohganz, H., Priemel, P. A., Lobmann, K., Nielsen, L. H., Laitinen, R., Mullertz, A., Van Den Mooter, G., Rades, T., 2014. Refining stability and dissolution rate of amorphous drug formulations. Expert Opin. Drug Deliv. 11, 977-989. doi: http://dx.doi.org/10.1517/17425247.2014.911728.
13. Guerrieri, P., Rumondor, A. C. F., Li, T., Taylor, L. S., 2010. Analysis of relationships between solid-state properties, counterion, and developability of pharmaceutical salts. AAPS PharmSciTech 11, 1212-1222. doi: http://dx.doi.org/10.1208/s12249-010-9499-4.
14. Ha, E.-S., Choo, G.-H., Baek, I.-H., Kim, M.-S., 2014. Formulation, characterization, and in vivo evaluation of celecoxib-pvp solid dispersion nanoparticles using supercritical antisolvent process. Molecules 19, 20325-20339. doi: http://dx. doi.org/10.3390/molecules191220325.
15. Halake, K., Birajdar, M., Kim, B. S., Bae, H., Lee, C., Kim, Y. J., Kim, S., Kim, H. J., Ahn, S., An, S. Y., Lee, J., 2014. Recent application developments of water-soluble synthetic polymers. J. Ind. Eng. Chem. 20, 3913-3918. doi: http://dx.doi.org/10.1016/j.jiec.2014.01.006.
16. Hancock, B. C., Zograf, G., 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 86, 1-12. doi: http://dx.doi.org/10.1021/js9601896.
17. Homayouni, A., Sadeghi, F., Varshosaz, J., Garekani, H. A., Nokhodchi, A., 2014. Comparing various techniques to produce micro/nanoparticles for enhancing the dissolution of celecoxib containing PVP. Eur. J. Pharm. Biopharm. 88, 261-274. doi: http://dx.doi.org/10.1016/j.ejpb.2014.05.022.
18. Iannuccelli, V., Coppi, G., Leo, E., Fontana, F., Bernabei, M. T., 2000. PVP solid dispersions for the controlled release of furosemide from a floating multiple-unit system. Drug Dev. Ind. Pharm. 26, 595-603. doi: http://dx.doi.org/10.1081/ddc-100101274.
19. Kanaujia, P., Lau, G., Ng, W. K., Widjaja, E., Hanefeld, A., Fischbach, M., Maio, M., Tan, R. B. H., 2011. Nanoparticle formation and growth during in vitro dissolution of ketoconazole solid dispersion. J. Pharm. Sci. 100, 2876-2885. doi: http://dx.doi.org/10.1002/jps.22491.
20. Konno, H., Taylor, L. S., 2006. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J. Pharm. Sci. 95, 2692-2705. doi: http://dx.doi.org/10.1002/jps.20697.
21. Laitinen, R., Lobmann, K., Strachan, C. J., Grohganz, H., Rades, T., 2013. Emerging trends in the stabilization of amorphous drugs. Int. J. Pharm. 453, 65-79. doi: http://dx.doi.org/10.1016/j.ijpharm.2012.04.066.
22. Marsac, P. J., Konno, H., Taylor, L. S., 2006. A comparison of the physical stability of amorphous felodipine and nifedipine systems. Pharm. Res. 23, 2306-2316. doi: http://dx.doi.org/10.1007/s11095-006-9047-9.
23. Matsuda, Y., Tatsumi, E., Thermal, S., 1990. Physicochemical characterization of furosemide modifications. Int. J. Pharmceutics 60, 11-26.
24. Miller, J. M., Beig, A., Carr, R. A., Spence, J. K., Dahan, A., 2012. A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. Mol. Pharm. 9, 2009-2016. doi: http://dx.doi.org/10.1021/mp300104s.
25. Newman, A., Knipp, G., Zografi, G., 2011. Assessing the performance of amorphous solid dispersions. J. Pharm. Sci. 101, 1355-1377. doi: http://dx.doi.org/10.1002/jps.23031.
26. Nielsen, L. H., Gordon, S., Holm, R., Selen, A., Rades, T., Mullertz, A., 2013a. Preparation of an amorphous sodium furosemide salt improves solubility and dissolution rate and leads to a faster T-max after oral dosing to rats. Eur. J. Pharm. Biopharm. 85, 942-951. doi: http://dx.doi.org/10.1016/j. ejpb.2013.09.002.
27. Nielsen, L. H., Gordon, S., Pajander, J. P., Ostergaard, J., Rades, T., Mullertz, A., 2013b. Biorelevant characterisation of amorphous furosemide salt exhibits conversion to a furosemide hydrate during dissolution. Int. J. Pharm. 457, 14-24. doi: http://dx.doi.org/10.1016/j.ijpharm.2013.08.029.
28. Nielsen, L. H., Rades, T., Müllertz, A., 2013c. Characterization during storage and dissolution of Solid dispersions containing furosemide and hydroxypropyl methylcellulose. J. Drug Deliv. Sci Technol. 23, 409-415.
29. Noyes, A. A., Whitney, W. R., 1897. The rateofsolution ofsolid substancesin theirown solutions. J. Am. Chem. Soc. 19, 930-934.
30. Patterson, J. E., James, M. B., Forster, A. H., Lancaster, R. W., Butler, J. M., Rades, T., 2005. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. J. Pharm. Sci. 94, 1998-2012. doi: http://dx.doi.org/10.1002/jps.20424.
31. Paudel, A., Worku, Z. A., Guns, J. M. S., Guns, S., Van Den Mooter, G., 2013. Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations. Int. J. Pharm. 453, 253-284. doi: http://dx.doi.org/10.1016/j.ijpharm.2012.07.015.
32. Savolainen, M., Kogermann, K., Heinz, A., Aaltonen, J., Peltonen, L., Strachan, C., Yliruusi, J., 2009. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Eur. J. Pharm. Biopharm. 71, 71-79. doi: http://dx.doi.org/10.1016/j.ejpb.2008.06.001.
33. Van Den Mooter, G., Wuyts, M., Blaton, N., Busson, R., Grobet, P., Augustijns, P., Kinget, R., 2001. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur. J. Pharm. Sci. 12, 261-269. doi: http://dx.doi.org/10.1016/s0928-0987 (00) 173-1.
34. Vasconcelos, T., Sarmento, B., Costa, P., 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov. Today 12, 1068-1075. doi: http://dx.doi.org/10.1016/j.drudis.2007.09.005.
35. Vo, C. L. N., Park, C., Lee, B. J., 2013. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 85, 799-813. doi: http://dx.doi.org/10.1016/j.ejpb.2013.09.007.
36. Yu, L. X., Carlin, A. S., Amidon, G. L., Hussain, A. S., 2004. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int. J. Pharm. 270, 221-227. doi: http://dx.doi.org/10.1016/j.ijpharm.2003.10.016.